Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

A novel therapeutic strategy for β-thalassemia.

Townes TM.

Blood. 2019 May 23;133(21):2245-2246. doi: 10.1182/blood-2019-02-900464. No abstract available.

PMID:
31122935
2.

Exogenous sickle erythrocytes combined with vascular disruption trigger disseminated tumor vaso-occlusion and lung tumor regression.

Sun CW, Wu LC, Wankhede M, Wang D, Thoerner J, Woody L, Sorg BS, Townes TM, Terman DS.

JCI Insight. 2019 Feb 19;4(7). pii: 125535. doi: 10.1172/jci.insight.125535. eCollection 2019 Apr 4.

3.

Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.

Mattapally S, Pawlik KM, Fast VG, Zumaquero E, Lund FE, Randall TD, Townes TM, Zhang J.

J Am Heart Assoc. 2018 Dec 4;7(23):e010239. doi: 10.1161/JAHA.118.010239.

4.

Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1.

Su H, Sun CW, Liu SM, He X, Hu H, Pawlik KM, Townes TM, Han X, Klug CA, Henary M, Chen Y, Li L, Zheng YG, Zhao X.

Blood Adv. 2018 Nov 13;2(21):2829-2836. doi: 10.1182/bloodadvances.2018020727.

5.

Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.

Devadasan D, Sun CW, Westin ER, Wu LC, Pawlik KM, Townes TM, Goldman FD.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1554-1562. doi: 10.1016/j.bbmt.2018.04.011. Epub 2018 Apr 21.

6.

Elevated p53 Activities Restrict Differentiation Potential of MicroRNA-Deficient Pluripotent Stem Cells.

Liu Z, Zhang C, Skamagki M, Khodadadi-Jamayran A, Zhang W, Kong D, Chang CW, Feng J, Han X, Townes TM, Li H, Kim K, Zhao R.

Stem Cell Reports. 2017 Nov 14;9(5):1604-1617. doi: 10.1016/j.stemcr.2017.10.006.

7.

Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.

Kasztan M, Fox BM, Speed JS, De Miguel C, Gohar EY, Townes TM, Kutlar A, Pollock JS, Pollock DM.

J Am Soc Nephrol. 2017 Aug;28(8):2443-2458. doi: 10.1681/ASN.2016070711. Epub 2017 Mar 27.

8.

Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.

Kingery JR, Hamid T, Lewis RK, Ismahil MA, Bansal SS, Rokosh G, Townes TM, Ildstad ST, Jones SP, Prabhu SD.

Basic Res Cardiol. 2017 Mar;112(2):19. doi: 10.1007/s00395-017-0609-2. Epub 2017 Feb 25.

9.

Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury Response.

Giordano S, Zhao X, Chen YF, Litovsky SH, Hage FG, Townes TM, Sun CW, Wu LC, Oparil S, Xing D.

Stem Cells Transl Med. 2017 Apr;6(4):1168-1177. doi: 10.1002/sctm.16-0316. Epub 2017 Feb 24.

10.

Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains.

Shao Z, Yao C, Khodadadi-Jamayran A, Xu W, Townes TM, Crowley MR, Hu K.

Cell Rep. 2016 Sep 20;16(12):3138-3145. doi: 10.1016/j.celrep.2016.08.060.

11.

Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction.

Li C, Ding L, Sun CW, Wu LC, Zhou D, Pawlik KM, Khodadadi-Jamayran A, Westin E, Goldman FD, Townes TM.

Sci Rep. 2016 Jul 27;6:30422. doi: 10.1038/srep30422.

12.

Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo.

Sun CW, Willmon C, Wu LC, Knopick P, Thoerner J, Vile R, Townes TM, Terman DS.

Front Oncol. 2016 Jul 8;6:166. doi: 10.3389/fonc.2016.00166. eCollection 2016.

13.

The AS-RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation.

Tran NT, Su H, Khodadadi-Jamayran A, Lin S, Zhang L, Zhou D, Pawlik KM, Townes TM, Chen Y, Mulloy JC, Zhao X.

EMBO Rep. 2016 Jun;17(6):887-900. doi: 10.15252/embr.201541970. Epub 2016 Apr 26.

14.

The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis.

Shao Z, Zhang R, Khodadadi-Jamayran A, Chen B, Crowley MR, Festok MA, Crossman DK, Townes TM, Hu K.

Nat Commun. 2016 Mar 7;7:10869. doi: 10.1038/ncomms10869.

15.

The histone H2A deubiquitinase Usp16 regulates hematopoiesis and hematopoietic stem cell function.

Gu Y, Jones AE, Yang W, Liu S, Dai Q, Liu Y, Swindle CS, Zhou D, Zhang Z, Ryan TM, Townes TM, Klug CA, Chen D, Wang H.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E51-60. doi: 10.1073/pnas.1517041113. Epub 2015 Dec 22.

16.

Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species.

Heimlich JB, Speed JS, O'Connor PM, Pollock JS, Townes TM, Meiler SE, Kutlar A, Pollock DM.

Br J Pharmacol. 2016 Jan;173(2):386-95. doi: 10.1111/bph.13380.

17.

Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting.

Chang CW, Lai YS, Westin E, Khodadadi-Jamayran A, Pawlik KM, Lamb LS Jr, Goldman FD, Townes TM.

Cell Rep. 2015 Sep 8;12(10):1668-77. doi: 10.1016/j.celrep.2015.08.013. Epub 2015 Aug 28.

18.

Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells.

Chang CW, Lai YS, Lamb LS Jr, Townes TM.

PLoS One. 2014 May 14;9(5):e97335. doi: 10.1371/journal.pone.0097335. eCollection 2014.

19.

The histone H2A deubiquitinase Usp16 regulates embryonic stem cell gene expression and lineage commitment.

Yang W, Lee YH, Jones AE, Woolnough JL, Zhou D, Dai Q, Wu Q, Giles KE, Townes TM, Wang H.

Nat Commun. 2014 May 2;5:3818. doi: 10.1038/ncomms4818.

20.

USP49 deubiquitinates histone H2B and regulates cotranscriptional pre-mRNA splicing.

Zhang Z, Jones A, Joo HY, Zhou D, Cao Y, Chen S, Erdjument-Bromage H, Renfrow M, He H, Tempst P, Townes TM, Giles KE, Ma L, Wang H.

Genes Dev. 2013 Jul 15;27(14):1581-95. doi: 10.1101/gad.211037.112. Epub 2013 Jul 3.

21.

FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin.

Kode A, Mosialou I, Silva BC, Rached MT, Zhou B, Wang J, Townes TM, Hen R, DePinho RA, Guo XE, Kousteni S.

J Clin Invest. 2012 Oct;122(10):3490-503. doi: 10.1172/JCI64906. Epub 2012 Sep 4.

22.

Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells.

Young MA, Larson DE, Sun CW, George DR, Ding L, Miller CA, Lin L, Pawlik KM, Chen K, Fan X, Schmidt H, Kalicki-Veizer J, Cook LL, Swift GW, Demeter RT, Wendl MC, Sands MS, Mardis ER, Wilson RK, Townes TM, Ley TJ.

Cell Stem Cell. 2012 May 4;10(5):570-82. doi: 10.1016/j.stem.2012.03.002. Epub 2012 Apr 26.

23.

Heme-regulated eIF2α kinase activated Atf4 signaling pathway in oxidative stress and erythropoiesis.

Suragani RN, Zachariah RS, Velazquez JG, Liu S, Sun CW, Townes TM, Chen JJ.

Blood. 2012 May 31;119(22):5276-84. doi: 10.1182/blood-2011-10-388132. Epub 2012 Apr 12.

24.

SRY (sex determining region Y)-box2 (Sox2)/poly ADP-ribose polymerase 1 (Parp1) complexes regulate pluripotency.

Lai YS, Chang CW, Pawlik KM, Zhou D, Renfrow MB, Townes TM.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3772-7. doi: 10.1073/pnas.1108595109. Epub 2012 Feb 23.

25.

PRC2 complexes with JARID2, MTF2, and esPRC2p48 in ES cells to modulate ES cell pluripotency and somatic cell reprogramming.

Zhang Z, Jones A, Sun CW, Li C, Chang CW, Joo HY, Dai Q, Mysliwiec MR, Wu LC, Guo Y, Yang W, Liu K, Pawlik KM, Erdjument-Bromage H, Tempst P, Lee Y, Min J, Townes TM, Wang H.

Stem Cells. 2011 Feb;29(2):229-40. doi: 10.1002/stem.578.

26.

Posttranscriptional control of type I interferon genes by KSRP in the innate immune response against viral infection.

Lin WJ, Zheng X, Lin CC, Tsao J, Zhu X, Cody JJ, Coleman JM, Gherzi R, Luo M, Townes TM, Parker JN, Chen CY.

Mol Cell Biol. 2011 Aug;31(16):3196-207. doi: 10.1128/MCB.05073-11. Epub 2011 Jun 20.

27.

Negative regulation of IRF7 activation by activating transcription factor 4 suggests a cross-regulation between the IFN responses and the cellular integrated stress responses.

Liang Q, Deng H, Sun CW, Townes TM, Zhu F.

J Immunol. 2011 Jan 15;186(2):1001-10. doi: 10.4049/jimmunol.1002240. Epub 2010 Dec 8.

28.

KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching.

Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM.

Nat Genet. 2010 Sep;42(9):742-4. doi: 10.1038/ng.637. Epub 2010 Aug 1.

PMID:
20676097
29.

Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells.

Chang CW, Lai YS, Pawlik KM, Liu K, Sun CW, Li C, Schoeb TR, Townes TM.

Stem Cells. 2009 May;27(5):1042-9. doi: 10.1002/stem.39.

30.

Gene replacement therapy for sickle cell disease and other blood disorders.

Townes TM.

Hematology Am Soc Hematol Educ Program. 2008:193-6. doi: 10.1182/asheducation-2008.1.193.

PMID:
19074080
31.

Global reorganization of replication domains during embryonic stem cell differentiation.

Hiratani I, Ryba T, Itoh M, Yokochi T, Schwaiger M, Chang CW, Lyou Y, Townes TM, Schübeler D, Gilbert DM.

PLoS Biol. 2008 Oct 7;6(10):e245. doi: 10.1371/journal.pbio.0060245.

32.

SNO-hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation.

Isbell TS, Sun CW, Wu LC, Teng X, Vitturi DA, Branch BG, Kevil CG, Peng N, Wyss JM, Ambalavanan N, Schwiebert L, Ren J, Pawlik KM, Renfrow MB, Patel RP, Townes TM.

Nat Med. 2008 Jul;14(7):773-7. doi: 10.1038/nm1771. Epub 2008 May 30.

33.

ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons in vitro and in vivo.

Lange PS, Chavez JC, Pinto JT, Coppola G, Sun CW, Townes TM, Geschwind DH, Ratan RR.

J Exp Med. 2008 May 12;205(5):1227-42. doi: 10.1084/jem.20071460. Epub 2008 May 5.

34.

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.

Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R.

Science. 2007 Dec 21;318(5858):1920-3. Epub 2007 Dec 6.

35.

Alterations in expression and chromatin configuration of the alpha hemoglobin-stabilizing protein gene in erythroid Kruppel-like factor-deficient mice.

Pilon AM, Nilson DG, Zhou D, Sangerman J, Townes TM, Bodine DM, Gallagher PG.

Mol Cell Biol. 2006 Jun;26(11):4368-77.

36.

Correction of sickle cell disease by homologous recombination in embryonic stem cells.

Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM.

Blood. 2006 Aug 15;108(4):1183-8. Epub 2006 Apr 25.

37.

Differential binding of erythroid Krupple-like factor to embryonic/fetal globin gene promoters during development.

Zhou D, Pawlik KM, Ren J, Sun CW, Townes TM.

J Biol Chem. 2006 Jun 9;281(23):16052-7. Epub 2006 Apr 10.

38.

Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.

Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM.

Oncogene. 2005 Feb 24;24(9):1491-500.

39.

Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.

Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, Sorscher EJ.

Cancer Res. 2004 Sep 15;64(18):6610-5.

40.

Rapid tagging of endogenous mouse genes by recombineering and ES cell complementation of tetraploid blastocysts.

Zhou D, Ren JX, Ryan TM, Higgins NP, Townes TM.

Nucleic Acids Res. 2004 Sep 8;32(16):e128.

41.

ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome.

Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G.

Cell. 2004 Apr 30;117(3):387-98.

42.

A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin.

Levasseur DN, Ryan TM, Reilly MP, McCune SL, Asakura T, Townes TM.

J Biol Chem. 2004 Jun 25;279(26):27518-24. Epub 2004 Apr 14.

43.

Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4.

Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, Abcouwer SF.

J Biol Chem. 2004 Apr 9;279(15):14844-52. Epub 2004 Jan 26.

44.

Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.

Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA 3rd, Sorscher EJ, Townes TM, Waud WR, Ealick SE.

Chem Biol. 2003 Dec;10(12):1173-81.

PMID:
14700625
45.
46.

Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization.

Aslan M, Ryan TM, Townes TM, Coward L, Kirk MC, Barnes S, Alexander CB, Rosenfeld SS, Freeman BA.

J Biol Chem. 2003 Feb 7;278(6):4194-204. Epub 2002 Oct 24.

47.

Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen.

Bradley MB, Sattler RM, Raftopoulos H, Ward M, Grossman IR, Townes TM, Ryan TA, Bank A.

Biol Blood Marrow Transplant. 2002;8(8):453-61.

48.
49.
50.

Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15215-20.

Supplemental Content

Loading ...
Support Center